David Zacks

Company: ONL Therapeutics

Job title: Chief Scientific Officer/Chief Medical Officer

Seminars:

Examining a Novel Fas Receptor Inhibitor for Dry AMD 10:30 am

Discussing the pre-clinical data regarding the role of Fas in retinal disease and AMD Discussing the development of ONL1204, a novel inhibitor of the Fas receptor Discussing the results of the Phase 1 study of ONL1204 in patients with GA secondary to AMD and the upcoming Phase 2 trialRead more

day: Conference Day Two

Fire-Side Chat: Discussing the Journey of Gaining Approval for GA Drugs & Current Challenges In the Market 1:00 pm

Discussing the path to gain approval for complement inhibitors for GA by the FDA and the rejections from the EMA Minimizing toxic side effects and reducing retinal inflammation when delivering via intravitreal injections Debating the optimal less invasive, longer lasting administration route to reduce frequence of injections for elderly patient population Understanding how the GA…Read more

day: Conference Day Two